UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000016991 |
|---|---|
| Receipt number | R000019718 |
| Scientific Title | Phase II trial (Investigator-initiated clinical trial) of CH5424802 in patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma |
| Date of disclosure of the study information | 2015/04/01 |
| Last modified on | 2020/11/20 16:21:41 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II trial (Investigator-initiated clinical trial) of CH5424802 in patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma
Acronym
Investigator-initiated trial of CH5424802 against relapsed or refractory ALK-positive ALCL
Scientific Title
Phase II trial (Investigator-initiated clinical trial) of CH5424802 in patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma
Scientific Title:Acronym
Investigator-initiated trial of CH5424802 against relapsed or refractory ALK-positive ALCL
Region
| Japan |
Condition
Condition
Relapsed or refractory ALK-positive anaplastic large cell lymphoma
Classification by specialty
| Hematology and clinical oncology | Pediatrics |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy, safety, and pharmacokinetics of alectinib hydrochloride in patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
Overall response rate determined by Independent Review Facility
Key secondary outcomes
Pharmacokinetics of CH5424802
The first safety evaluation
Complete remission rate
Duration of response
Progression-free survival,
Event free survival,
Overall survival
Adverse event and adverse drug reaction
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
The investigational product is administered orally at 300 mgb.i.d after breakfast and dinner for 21 days, which is regarded as 1 cycle. In subjects weighing less than 35 kg, the investigational product is administered at 150 mg b.i.d after breakfast and dinner.
The administration is terminated after a maximum of 16 cycles, in principle, but may be continued over 17 or more cycles in subjects judged to require the treatment.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 6 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Patients aged 6 years or older at consent and judged by the investigator/subinvestigator to be able to take capsules.
2) Patients definitively diagnosed with ALK-positive ALCL by histological examination.
Note: Judgments are made by immunohistochemical staining of tissues collected at the initial examination or relapse.
3) Patients who can provide pathological tissues of lymphoma for central review.
4) Patients in whom the condition was judged to be PD during standard chemotherapy, CR/PR could not be achieved after the therapy, or recurrence or re-exacerbation was observed after standard chemotherapy.
5) Patients having measurable lesions defined by the Revised Response Criteria for Malignant Lymphoma according to the evaluation by the implementing medical facility.
6) Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2.
7) Patients expected to survive for 3 months or longer at the time of consent.
8) Patients who fulfill all the following criteria on the clinical laboratory tests at the screening examination. Those who have not been administered a genetically engineered human granulocyte colony-stimulating factor (G-CSF) preparation or have not received blood transfusion within 1 week before examination of the neutrophil and platelet counts and retain normal functions of major organs.
1.Neutrophil count: >=1,500/uL
2.Platelet count: >=75,000/uL
3.Serum bilirubin level: <1.5 times the upper limit of normal (ULN) of the facility
4.Serum creatinine level: <=1.5 times the ULN
5.Alanine aminotransferase (ALT) and aspartic aminotransferase (AST) levels: <=2.5 times the ULN
9) Written consent to participate in this clinical trial has been given by the subject in person or by a legal guardian (when the subject is younger than 20 years at consent).
Key exclusion criteria
1) Patients in whom the latest diagnosis is primary cutaneous ALCL/2)Patients in whom active viral, bacterial, or fungal infection has been observed within 2 weeks before the first administration of the investigational product/3) Patients with poorly controlled diabetes/4) Patients with a history or complication of another malignant neoplasm that has not been cured for 3 years or longer/5) Patients with CNS lesions/6) Patients showing signs or symptoms suggestive of PML/7) Patients with a history of severe hypersensitivity or allergy/8) Patients positive for HIV antibody, HBs antigen, HBs antibody, HBc antibody, or HVC antibody/9) Patients with liver cirrhosis/10) Patients who have received ASCT within 12 weeks before the first administration of the investigational product/11) Patients who have received allogeneic hematopoietic stem-cell transplantation/12) Patients who have received treatment for a malignant neoplasm within 4 weeks before the first administration of the investigational product/13) Patients who have been administered an adrenocorticosteroid hormone preparation for the treatment of lymphoma within 7 days before the first administration of the investigational product./14) Patients administered another investigational product or treated using an investigational instrument within 4 weeks./15) Patients who received a treatment specifically targeting ALK in the past./16) Patients known to have hypersensitivity to additives contained in the investigational product./17) Patients who are pregnant, breast-feeding, or may be pregnant, or do not consent to contraception for 6 months after the last administration of the investigational product./18) Patients who have a disability that impairs their ability to consent in writing or conform to the trial procedure./19) Patients who have been judged by the investigator to be inappropriate for participation in this clinical trial for other reasons.
Target sample size
10
Research contact person
Name of lead principal investigator
| 1st name | Hirokazu |
| Middle name | |
| Last name | Nagai |
Organization
National Hospital Organization Nagoya Medical Center
Division name
Department of Hematology and Oncology Research, Clinical Research Center
Zip code
4600001
Address
4-1-1 Sannomaru Nakaku Nagoya, Aichi, Japan
TEL
052-951-1111
nagaih@nnh.hosp.go.jp
Public contact
Name of contact person
| 1st name | Yutaka |
| Middle name | |
| Last name | Ito |
Organization
National Hospital Organization Nagoya Medical Center
Division name
Department of Clinical Research Management, Clinical Research Center
Zip code
4600001
Address
4-1-1 Sannomaru Nakaku Nagoya, Aichi, Japan
TEL
052-951-1111
Homepage URL
alc.office@nnh.go.jp
Sponsor or person
Institute
National Hospital Organization Nagoya Medical Center
Hirokazu Nagai
St.Marianna University School of Medicine Hospital
Tetsuya Mori
National Hospital Oganization Kyusyu cancer center
Che Irusun
Institute
Department
Personal name
Funding Source
Organization
Chugai Inc.
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Nagoya Medical Center
Address
4-1-1,Sannomaru,Naka-ku,Nagoya-shi Aichi-ken,Japan
Tel
052-951-1111
study.office@nnh.go.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 04 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
10
Results
in preparation
Results date posted
| 2019 | Year | 04 | Month | 03 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Main results already published
Date of protocol fixation
| 2015 | Year | 02 | Month | 18 | Day |
Date of IRB
| 2015 | Year | 03 | Month | 12 | Day |
Anticipated trial start date
| 2015 | Year | 04 | Month | 01 | Day |
Last follow-up date
| 2020 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
| 2018 | Year | 04 | Month | 11 | Day |
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2015 | Year | 03 | Month | 31 | Day |
Last modified on
| 2020 | Year | 11 | Month | 20 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019718
